Navigation Links
Humanized Antibody Therapy Found Highly Effective in Easing RA Symptoms

Medical University of Vienna researchers have shown that nearly half of patients with rheumatoid arthritis (RA), who receive tocilizumab in addition to ongoing methotrexate therapy , showed a 50 per cent improvement in the symptoms at 24 weeks.

Also one fifth of the patients achieved a 70 per cent improvement in symptoms in the same period during the study, which was presented at EULAR 2007, the Annual European Congress of Rheumatology in Barcelona.

These data show the potential of tocilizumab as a novel and attractive approach to treating RA. The symptom improvements observed across both 4mg/kg and 8mg/kg doses show that tocilizumab offers significant promise to patients with moderate and severe RA, said lead researcher Dr. Josef Smolen.

The researchers say that significant improvement in symptoms was observed in all patients receiving tocilizumab and methotrexate, compared to placebo and methotrexate.

They observed that 79.5 per cent of patients receiving tocilizumab 8mg/kg, and 61.9 per cent receiving 4mg/kg tocilizumab had achieved a good/moderate EULAR response, in comparison with placebo subjects.

A reduction in Disease Activity Score was also observed from two weeks onwards in both tocilizumab groups, say the researchers.

The study involved 623 patients with sustained moderate to severe RA despite long standing treatment with methotrexate. The subjects were permitted concurrent treatment with methotrexate at their pre-study dose, though treatment with all other disease modifying anti-rheumatic drugs was discontinued at the beginning of the trial.

Tocilizumab is a novel humanised anti human interleukin 6 (IIL-6) receptor monoclonal antibody, a cytokine involved in the pathogenesis of RA.


'"/>




Page: 1

Related medicine news :

1. Human Antibody That Can Block SARS
2. Therapeutic Monoclonal Antibody Production Is More Profitable Than Small Molecule Drugs
3. Cuba Registers New Antibody
4. Single Sugar Enables Antibody to Treat Inflammation
5. Monoclonal Antibody based system for Anthrax detection
6. Monoclonal Antibody Reduces Exacerbations in Asthmatics
7. Anti-rejection Therapy a Boon for Patients With "anti-donor" Antibody Levels
8. Antibody Therapy Prevents Type 1 Diabetes
9. New Antibody for EGFR Causes Lung Cancer Regression
10. J591- an Antibody Exclusively Targets Tumors
11. Antibody-based Therapies Effective at Controlling Malaria
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/9/2016)... ... December 09, 2016 , ... MEDI+SIGN®, a provider ... that a new solution for Emergency Departments (ED) has been added to their ... Emergency Department examination rooms, and with a simplified pallet of information available to ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... with distinction by the Undersea and Hyperbaric Medical Society (UHMS), the leading authority ... care and patient safety. Only a few hospitals and facilities have earned this ...
(Date:12/8/2016)... ... December 08, 2016 , ... Seavest ... Property owned by an affiliate of Seavest, has won a prestigious national healthcare ... Chester County ambulatory care center (ACC) was named “Best New Development, MOBs and ...
(Date:12/8/2016)... ... December 08, 2016 , ... David J. Dykeman , ... Greenberg Traurig, LLP, will speak at DeviceTalks West, Dec. 12, 2016, at the Fairmont ... and attorneys from the firm’s global Life Sciences & Medical Technology Group have been ...
(Date:12/8/2016)... ... 2016 , ... Catalent Pharma Solutions, the leading global provider ... products, today announced that it had joined the Pharmaceutical Supply Chain Initiative (PSCI). ... unite pharmaceutical and healthcare companies that share a vision of better, social, environmental ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... , Dec. 8, 2016 KEY FINDINGS ... the largest share of the market in 2016 and ... dominance can be attributed to a large number of ... (US hold the largest share in the patient temperature ... benefits such as reducing loss of blood during surgeries, ...
(Date:12/8/2016)... 8, 2016 Research and Markets has announced ... Trends - Adhesion Type, Application, Usability - Forecast to 2025" ... , ... Market is poised to grow at a CAGR of around 3.2% ... market is witnessing include advancements in extracellular microelectrode arrays and intracellular ...
(Date:12/8/2016)... Quebec , Dec. 8, 2016  Valeant ... and TSX: VRX) ("Valeant") today announced positive results ... clinical study to assess the safety and efficacy ... the treatment of plaque psoriasis. ... subjects with moderate to severe psoriasis, IDP-118 showed ...
Breaking Medicine Technology: